These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38999423)

  • 1. Evaluating Factor VIII Concentrates Using Clot Waveform Analysis.
    Wada H; Shiraki K; Matsumoto T; Shimpo H; Sakano Y; Nishii H; Tamaki S; Suzuki K; Tawara I; Yamashita Y; Shimaoka M
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999423
    [No Abstract]   [Full Text] [Related]  

  • 2. The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay.
    Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Sakano Y; Nishii H; Shimaoka M
    Clin Appl Thromb Hemost; 2021; 27():1076029620976913. PubMed ID: 33606948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
    Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clot Waveform Analysis for Hemostatic Abnormalities.
    Wada H; Shiraki K; Matsumoto T; Shimpo H; Shimaoka M
    Ann Lab Med; 2023 Nov; 43(6):531-538. PubMed ID: 37387486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis.
    Fukui S; Wada H; Ikeda K; Kobayashi M; Shimada Y; Nakazawa Y; Mizutani H; Ichikawa Y; Nishiura Y; Moritani I; Yamanaka Y; Inoue H; Shimaoka M; Shimpo H; Shiraki K
    Clin Appl Thromb Hemost; 2024; 30():10760296241246002. PubMed ID: 38591954
    [No Abstract]   [Full Text] [Related]  

  • 6. A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms.
    Kobayashi M; Wada H; Fukui S; Mizutani H; Ichikawa Y; Shiraki K; Moritani I; Inoue H; Shimaoka M; Shimpo H
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura.
    Wada H; Ichikawa Y; Ezaki M; Shiraki K; Moritani I; Yamashita Y; Matsumoto T; Masuya M; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
    Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor.
    Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Shimaoka M
    Thromb Res; 2020 Sep; 193():146-153. PubMed ID: 32559572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients.
    Hasegawa M; Tone S; Wada H; Naito Y; Matsumoto T; Yamashita Y; Shimaoka M; Sudo A
    Clin Appl Thromb Hemost; 2021; 27():10760296211012094. PubMed ID: 34027710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
    Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
    Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Detection of Hypercoagulability in Patients with Acute Cerebral Infarction Using a Clot Waveform Analysis.
    Kamon T; Horie S; Inaba T; Ito N; Shiraki K; Ichikawa Y; Ezaki M; Shimpo H; Shimaoka M; Nishigaki A; Shindo A; Wada H
    Clin Appl Thromb Hemost; 2023; 29():10760296231161591. PubMed ID: 36872898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
    Bowyer AE; Kitchen S; Ezban M
    J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.
    Kato K; Hatayama Y; Shimohiro H; Ichikawa H; Fukuda T
    Yonago Acta Med; 2022 Aug; 65(3):226-230. PubMed ID: 36061578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
    Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
    Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reagent Effects on the Activated Partial Thromboplastin Time Clot Waveform Analysis: A Multi-Centre Study.
    Wong WH; Tan CW; Abdul Khalid NB; Dalimoenthe NZ; Yip C; Tantanate C; Lim RD; Kim JH; Ng HJ
    Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
    Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
    Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.